88 related articles for article (PubMed ID: 10371156)
21. Dihydropyridine receptor of L-type Ca2+ channels: identification of binding domains for [3H](+)-PN200-110 and [3H]azidopine within the alpha 1 subunit.
Striessnig J; Murphy BJ; Catterall WA
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10769-73. PubMed ID: 1660150
[TBL] [Abstract][Full Text] [Related]
22. Voltage-dependent acceleration of Ca(v)1.2 channel current decay by (+)- and (-)-isradipine.
Berjukow S; Hering S
Br J Pharmacol; 2001 Aug; 133(7):959-66. PubMed ID: 11487504
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of dihydropyridine interaction with critical binding residues of L-type Ca2+ channel alpha 1 subunits.
Wappl E; Mitterdorfer J; Glossmann H; Striessnig J
J Biol Chem; 2001 Apr; 276(16):12730-5. PubMed ID: 11278630
[TBL] [Abstract][Full Text] [Related]
24. Differential sensitivities of CaV1.2 IIS5-S6 mutants to 1,4-dihydropyridine analogs.
Hui K; Kwok TC; Kostelecki W; Leen J; Roy PJ; Feng ZP
Eur J Pharmacol; 2009 Jan; 602(2-3):255-61. PubMed ID: 19068212
[TBL] [Abstract][Full Text] [Related]
25. Molecular determinants of drug binding and action on L-type calcium channels.
Hockerman GH; Peterson BZ; Johnson BD; Catterall WA
Annu Rev Pharmacol Toxicol; 1997; 37():361-96. PubMed ID: 9131258
[TBL] [Abstract][Full Text] [Related]
26. Molecular modeling of interactions of dihydropyridines and phenylalkylamines with the inner pore of the L-type Ca2+ channel.
Lipkind GM; Fozzard HA
Mol Pharmacol; 2003 Mar; 63(3):499-511. PubMed ID: 12606756
[TBL] [Abstract][Full Text] [Related]
27. A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine.
Miyashita Y; Furukawa T; Kamegaya E; Yoshii M; Nukada T
Eur J Pharmacol; 2010 Apr; 632(1-3):14-22. PubMed ID: 20097194
[TBL] [Abstract][Full Text] [Related]
28. L-type calcium channels: binding domains for dihydropyridines and benzothiazepines are located in close proximity to each other.
Brauns T; Prinz H; Kimball SD; Haugland RP; Striessnig J; Glossmann H
Biochemistry; 1997 Mar; 36(12):3625-31. PubMed ID: 9132014
[TBL] [Abstract][Full Text] [Related]
29. Key roles of Phe1112 and Ser1115 in the pore-forming IIIS5-S6 linker of L-type Ca2+ channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and action of Ca2+ channel agonists.
Yamaguchi S; Zhorov BS; Yoshioka K; Nagao T; Ichijo H; Adachi-Akahane S
Mol Pharmacol; 2003 Aug; 64(2):235-48. PubMed ID: 12869628
[TBL] [Abstract][Full Text] [Related]
30. Mapping of dihydropyridine binding residues in a less sensitive invertebrate L-type calcium channel (LCa v 1).
Senatore A; Boone A; Lam S; Dawson TF; Zhorov B; Spafford JD
Channels (Austin); 2011; 5(2):173-87. PubMed ID: 21487241
[TBL] [Abstract][Full Text] [Related]
31. L-type calcium channels: asymmetrical intramembrane binding domain revealed by variable length, permanently charged 1,4-dihydropyridines.
Bangalore R; Baindur N; Rutledge A; Triggle DJ; Kass RS
Mol Pharmacol; 1994 Oct; 46(4):660-6. PubMed ID: 7969044
[TBL] [Abstract][Full Text] [Related]
32. Fast activation of dihydropyridine-sensitive calcium channels of skeletal muscle. Multiple pathways of channel gating.
Ma J; González A; Chen R
J Gen Physiol; 1996 Sep; 108(3):221-32. PubMed ID: 8882865
[TBL] [Abstract][Full Text] [Related]
33. Homology model of dihydropyridine receptor: implications for L-type Ca(2+) channel modulation by agonists and antagonists.
Zhorov BS; Folkman EV; Ananthanarayanan VS
Arch Biochem Biophys; 2001 Sep; 393(1):22-41. PubMed ID: 11516158
[TBL] [Abstract][Full Text] [Related]
34. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
Chang CC; Cao S; Kang S; Kai L; Tian X; Pandey P; Dunne SF; Luan CH; Surmeier DJ; Silverman RB
Bioorg Med Chem; 2010 May; 18(9):3147-58. PubMed ID: 20382537
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of recombinant Ca2+ channels by benzothiazepines and phenylalkylamines: class-specific pharmacology and underlying molecular determinants.
Cai D; Mulle JG; Yue DT
Mol Pharmacol; 1997 May; 51(5):872-81. PubMed ID: 9145926
[TBL] [Abstract][Full Text] [Related]
36. Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity.
Schaller D; Gündüz MG; Zhang FX; Zamponi GW; Wolber G
Eur J Med Chem; 2018 Jul; 155():1-12. PubMed ID: 29843108
[TBL] [Abstract][Full Text] [Related]
37. Ca2+ channel sensitivity towards the blocker isradipine is affected by alternative splicing of the human alpha1C subunit gene.
Zühlke RD; Bouron A; Soldatov NM; Reuter H
FEBS Lett; 1998 May; 427(2):220-4. PubMed ID: 9607315
[TBL] [Abstract][Full Text] [Related]
38. Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.
Salomone S; Godfraind T
Br J Pharmacol; 1993 May; 109(1):100-6. PubMed ID: 8495233
[TBL] [Abstract][Full Text] [Related]
39. Structural model for dihydropyridine binding to L-type calcium channels.
Tikhonov DB; Zhorov BS
J Biol Chem; 2009 Jul; 284(28):19006-17. PubMed ID: 19416978
[TBL] [Abstract][Full Text] [Related]
40. Stereoselective characterization of the 1,4-dihydropyridine binding site at L-type calcium channels in the resting state and the opened/inactivated state.
Schleifer KJ
J Med Chem; 1999 Jun; 42(12):2204-11. PubMed ID: 10377225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
